The CD16A and CD16B mRNA level as potential immunological marker in colorectal cancer

The purpose of this study is to evaluate mRNA levels of genes encoding CD16A (FCGR3A) and CD16B (FCGR3B) in peripheral blood and tumors of colorectal cancer patients (CRC).Materials and methods. The study included 66 CRC patients from Nizhny Novgorod Regional Clinical Oncology Center and 111 people without cancer as a comparison group from Nizhny Novgorod Regional Blood Center named after N.Ya. Klimova. The mRNA relative levels in peripheral blood and tumor was detected by reverse transcription real-time polymerase chain reaction. The mRNA levels correlation and association with CRC clinical characteristics were assessed by statistic methods.Results. The study suggests that in the peripheral blood of CRC patients the levels of mRNA FCGR3A and FCGR3B were statistically significantly lower than in healthy individuals. The mRNA levels remained low at 7–10 days after surgery. The FCGR3A mRNA normalized level in the blood and tumors of CRC patients, as well as in the blood of healthy individuals, was several times higher than the FCGR3B mRNA level. At the II stage of tumor development in CRC patients, the FCGR3A and FCGR3B mRNA levels were statistically significantly decreased, but as the tumor progressed is normalized. Moderate degree of tumor differentiation was also characterized by a drop in mRNA levels of the tested genes. Reduced FCGR3A and FCGR3B mRNA levels in the blood of patients were observed in the absence of metastases. In tumor samples, FCGR3A mRNA was tested in 95.5% of cases, FCGR3B mRNA in 68.2% of cases. Progression of CRC was accompanied by an increase in FCGR3A mRNA level in tumors, the FCGR3B mRNA level did not change. Positive correlation of FCGR3A mRNA level with TNF and FOXP3 mRNA levels was found, which indicates the possible involvement of FCGR3A in the regulation of chronic inflammation in tumors of CRC patients.Conclusion. Changes in mRNA levels of genes encoding CD16A (FCGR3A) and CD16B (FCGR3A) molecules were detected in blood and tumor samples. The results indicate the potential for their use as monitoring immunological markers in CRC.

Download Full-text

CD16A and CD16B mRNA levels as a potential immunological marker in prostate cancer

10.18411/sr-05-12-2021-06 ◽

2021 ◽

Author(s):

Khalil Arioua

Keyword(s):

Prostate Cancer ◽

Peripheral Blood ◽

Mrna Level ◽

Mrna Levels ◽

Relative Level ◽

Immunological Markers ◽

Healthy Donors ◽

Genes Encoding ◽

Degree Of Differentiation ◽

Prostate Antigen

Introduction and purpose Understanding the movement of immune cells in prostate cancer is the best solution for development antitumor therapy. In our study, we will evaluate level mRNA CD16А (FCGR3A) and mRNA CD16B (FCGR3B) in patients diagnosing benign hyperplasia and patients diagnosing prostate cancer (Pc). Materials and methods In the study, we analyzed 240 samples of mRNA, 49 was the blood of healthy donors, 37 was the blood of prostate cancer patients and 62 tumors of prostate, 37 were blood of hyperplasia and 55 was tissue of hyperplasia, all patients treated in the Hospital 33 (Niznhy Novgord, Russia). The relative level of mRNA in peripheral blood and tumors was determined by the method of reverse transcription-polymerase chain reaction in real time. Results In the peripheral blood of patients with prostate cancer and patients with hyperplasia, the level of mRNA FCGR3A and FCGR3B was statistically significantly lower than in healthy individuals. The normalization of the CD16 level in the blood of healthy donors was higher The relative level of mRNA FCGR3A, FCGR3B was the highest in patients with Prostate antigen specific (PSA) from 10Ng/ml to 20Ng/ml. The higher level mRNA FCGR3A and FCGR3B was for patients with higher testosterone ≥8mmol/L. also a higher level of FCGR3A, FCGR3B was found in patients diagnosed with an adenopathy:, a higher size prostate and a higher Gleason Scores. The results of Classification based on the degree of differentiation shows that the level of mRNA FCGR3A and FCGR3B in patients with medium differentiation was higher and statistically significant than in patient with lower differentiation. Conclusion. The Changes in the mRNA level of genes encoding CD16A (FCGR3A) and CD16B (FCGR3A) was detected in blood and tumor samples. The results indicate the potential use of these indicators as monitoring immunological markers in hyperplasia and prostate cancer.

Download Full-text

A Novel Type of Blood Biomarker: Distinct Changes of Cytokine-Induced STAT Phosphorylation in Blood T Cells Between Colorectal Cancer Patients and Healthy Individuals

Cancers ◽

10.3390/cancers11081157 ◽

2019 ◽

Vol 11 (8) ◽

pp. 1157 ◽

Cited By ~ 3

Author(s):

Yun ◽

Lee ◽

Kim ◽

Chun ◽

Engleman ◽

...

Keyword(s):

Colorectal Cancer ◽

T Cells ◽

Peripheral Blood ◽

Immune Cell ◽

Flow Analysis ◽

Healthy Individuals ◽

Crc Screening ◽

Initial Cohort ◽

New Type ◽

Colorectal Cancer Patients

Background: Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide. Although early diagnosis and treatment is the most successful strategy for improving patient survival, feasible and sensitive blood biomarkers for CRC screening remain elusive. Methods: Sixty-five CRC patients and thirty-three healthy individuals were enrolled. Peripheral blood (PB) and tumor tissues from CRC patients, and PB from healthy individuals were subjected to immunophenotyping and phospho-flow analysis of cytokine-induced phosphorylated STAT (CIPS). Logistic regression was used as a classifier that separates CRC patients from healthy individuals. Results: The proportion of regulatory T cells was increased in PB from CRC patients compared to PB from healthy individuals (p < 0.05). Interestingly, peripheral T cells share several cytokine-induced phosphorylated STAT (CIPS) signatures with T cells from CRC tumor-sites. Additionally, a classifier was made using two signatures distinct between T cells from CRC patients and T cells from healthy individuals. The AUCs (area under curves) of the classifier were 0.88 in initial cohort and 0.94 in the additional validation cohort. Overall AUC was 0.94 with sensitivity of 91% and specificity of 88%. Conclusion: This study highlights that immune cell signatures in peripheral blood could offer a new type of biomarker for CRC screening.

Download Full-text